Diabetic Treatment Adherence

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01318564
First received: March 16, 2011
Last updated: January 23, 2014
Last verified: January 2014
  Purpose

The goal of this clinical research study is to test an investigational type of packaging for diabetes drugs called "unit-dose packaging." Researchers want to learn if unit-dose packaging can help patients with Type II diabetes to take their drugs on the proper schedule.


Condition Intervention
Endocrine System Diseases
Drug: Metformin
Behavioral: Questionnaires

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Treatment Adherence With Compliance Prompting Packaging

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Patients' Adherence to Unit Dose Packaging Devices [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Taking information from the electronic monitor device packages, adherence considered as a ratio of prescribed doses to doses taken.


Biospecimen Retention:   Samples With DNA

A fasting blood sample of 10 ml will be collected 2 days after randomization if the physician considers the test as a standard of care.


Estimated Enrollment: 120
Study Start Date: March 2011
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1: Unit-dose - Pill Bottle
Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
Drug: Metformin
500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
Behavioral: Questionnaires
Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
Other Name: Surveys
Group 2: Pill Bottle - Unit Dose
Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
Drug: Metformin
500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
Behavioral: Questionnaires
Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
Other Name: Surveys

  Hide Detailed Description

Detailed Description:

Study Background:

Some people find it difficult to take drugs on the proper schedule. For this reason, researchers want to learn if a different kind of drug packaging can help patients take their drugs more easily.

In unit-dose packaging, each pill is packaged in its own plastic bubble (called a "blister") on a package that has a calendar on it. This is designed to make it easier to keep track of when the pills should be taken.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will keep taking the same drugs that you are taking now. You will also keep taking those drugs on the same schedule that your doctor prescribed. The specific "study drugs" you may be taking are metformin, lisinopril, enalapril, atorvastatin, simvastatin, and aspirin.

You will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. You have an equal chance of being assigned to either group.

Group 1 will receive their study drugs in unit-dose packages (also called "reminder blister packages") from Visit 1 to Visit 2.

Group 2 will receive their study drugs in pill bottles from Visit 1 to Visit 2.

Data Collection on Pill Usage:

There are electronic sensors on each blister package and pill bottle. If you are using blister packages (Group 1), the sensors will record the dates and times that you remove pills from the blisters. If you are using pill bottles (Group 2), the sensors will record the dates and times that you open the bottles.

It is important that you do not remove the pills too early before your dose (for example, the night before), so that the proper time is recorded.

You should return the empty blister packages or bottles to the clinic at each study visit. When you return the empty packaging, researchers will be able to collect the data that the sensors recorded (times and dates).

Study Visits:

On Day 1 and after Month 3, you will complete a questionnaire. It includes questions about your overall health, daily activities, and moods. There are also questions about how you take your drugs and how you feel about your diabetes drugs such as metformin. This questionnaire should take about 30-45 minutes to complete.

Researchers will record the results of your routine blood sugar level tests performed on Day 1 and after Month 3. Researchers will also record the results of your routine cholesterol level blood tests on Day 1 and after Month 3. The purpose is to learn how the drugs may impact your health status.

At each visit your blood pressure will be measured 3 times. This will take about 15 min. If your questionnaire responses show that you may be having emotional difficulties or depression, you will receive contact information for the counseling staff in case you would like to speak with a counselor.

Study Databases:

Your questionnaire and blood test data will be kept confidential and will only be used for this study. The same is true for the pill/package usage data recorded by the electronic sensors.

The study data will be entered into password-protected databases. In the databases, your name and other identifying information will not be used. Instead, your study identification (ID) number will be used.

Length of Study Participation:

Your study participation will be over after you complete the questionnaire after Month 3.

This is an investigational study. Unit-dose packaging is an FDA-approved type of packing for certain other drugs. At this time and for these particular drugs, unit-dose packaging is only being used in research.

Up to 120 patients will take part in this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

General Internal Medicine/Ambulatory Clinics at UT MD Anderson Cancer Center in Houston, Texas Kelsey-Seybold Outpatient Clinics in Houston, Texas

Criteria

Inclusion Criteria:

  1. Adults of 18 years or older.
  2. Patients with type II Diabetes taking or eligible to start metformin with at least another medication for hypertension (Lisinopril or Enalapril), hyperlipidemia (atorvastatin or simvastatin) and/or aspirin.

Exclusion Criteria:

  1. Dementia
  2. Patients receiving current intravenous chemotherapy
  3. Pregnancy
  4. Patients residing in a nursing home
  5. Treatment with any type of Insulin
  6. Patients wanting to continue to use pill organizers for monitored medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01318564

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Maria Suarez-Almazor, MD,PHD UT MD Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01318564     History of Changes
Other Study ID Numbers: 2008-0242
Study First Received: March 16, 2011
Last Updated: January 23, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Type II Diabetes
Unit dose packaging devices
Metformin
Lisinopril
Enalapril
Atorvastatin
Lipitor
Simvastatin
Aspirin
Questionnaires

Additional relevant MeSH terms:
Endocrine System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014